Literature DB >> 9164589

Suppressive effect of mitragynine on the 5-methoxy-N,N-dimethyltryptamine-induced head-twitch response in mice.

K Matsumoto1, M Mizowaki, H Takayama, S Sakai, N Aimi, H Watanabe.   

Abstract

We investigated the effects of mitragynine, a major alkaloid isolated from the leaves of Mitragyna speciosa Korth (Rubiaceae), on the 5-HT2A receptor-mediated head-twitch response in mice. Intraperitoneal injection of mitragynine (5-30 mg/kg), as well as intraperitoneal injection of 5-HT2A receptor antagonist ritanserin, inhibited the 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT: 16 mg/kg, IP)-induced head-twitch response in a dose-dependent manner. In contrast, mitragynine affected neither head-weaving caused by 5-MeO-DMT, nor drug-free spontaneous motor activity. Pretreatment of mice with reserpine (5 mg/kg, IP), p-chlorophenylalanine (p-CPA, 300 mg/kg x 3 times, IP), or 6-hydroxydopamine (6-OHDA, 50 micrograms/mouse, ICV) plus nomifensine (5 mg/kg, IP) did not change the suppressant effect of mitragynine on the head-twitch response caused by 5-MeO-DMT. On the other hand, the alpha 2-adrenoceptor antagonists yohimbine (0.5 mg/kg, IP), and idazoxan (0.2 mg/kg, IP), significantly attenuated the suppressant effect of mitragynine. Lesion of central noradrenergic systems by 6-OHDA plus nomifensine did not alter the effect of idazoxan (0.2 mg/kg) on mitragynine-induced suppression of the head-twitch response. These results indicate that stimulation of postsynaptic alpha 2-adrenoceptor, blockade of 5-HT2A receptors, or both, are involved in suppression of 5-HT2A receptor-mediated head-twitch response by mitragynine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9164589     DOI: 10.1016/s0091-3057(96)00314-0

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  12 in total

1.  Methanolic extract of Mitragyna speciosa Korth leaf inhibits ethanol seeking behaviour in mice: involvement of antidopaminergic mechanism.

Authors:  Kamini Vijeepallam; Vijayapandi Pandy; Dharmani Devi Murugan; Murali Naidu
Journal:  Metab Brain Dis       Date:  2019-08-08       Impact factor: 3.584

Review 2.  Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.

Authors:  Hong-Wu Shen; Xi-Ling Jiang; Jerrold C Winter; Ai-Ming Yu
Journal:  Curr Drug Metab       Date:  2010-10       Impact factor: 3.731

3.  Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa).

Authors:  Friedrich G Kapp; Hans H Maurer; Volker Auwärter; Martin Winkelmann; Maren Hermanns-Clausen
Journal:  J Med Toxicol       Date:  2011-09

4.  Mitragynine, bioactive alkaloid of kratom, reduces chemotherapy-induced neuropathic pain in rats through α-adrenoceptor mechanism.

Authors:  Jeffery D Foss; Sunil U Nayak; Christopher S Tallarida; Daniel J Farkas; Sara J Ward; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2020-02-27       Impact factor: 4.492

5.  Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract.

Authors:  Anne-Christin Stolt; Helmut Schröder; Hartmud Neurath; Gisela Grecksch; Volker Höllt; Markus R Meyer; Hans H Maurer; Nancy Ziebolz; Ursula Havemann-Reinecke; Axel Becker
Journal:  Psychopharmacology (Berl)       Date:  2013-07-12       Impact factor: 4.530

6.  Physiological dependence to mitragynine indicated by a rapid cross-dependence procedure with heroin-dependent mice.

Authors:  Kai Yue; Jonathan L Katz; Xiji Shu
Journal:  Psychopharmacology (Berl)       Date:  2022-02-02       Impact factor: 4.530

7.  Research on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice.

Authors:  Olga Zhuk; Izabela Jasicka-Misiak; Anna Poliwoda; Anastasia Kazakova; Vladlena V Godovan; Marek Halama; Piotr P Wieczorek
Journal:  Toxins (Basel)       Date:  2015-03-27       Impact factor: 4.546

8.  Mitragyna speciosa Leaf Extract Exhibits Antipsychotic-Like Effect with the Potential to Alleviate Positive and Negative Symptoms of Psychosis in Mice.

Authors:  Kamini Vijeepallam; Vijayapandi Pandy; Thubasni Kunasegaran; Dharmani D Murugan; Murali Naidu
Journal:  Front Pharmacol       Date:  2016-12-06       Impact factor: 5.810

9.  Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant.

Authors:  Alessandro E Vento; Simone de Persis; Sergio De Filippis; Fabrizio Schifano; Flavia Napoletano; John M Corkery; Georgios D Kotzalidis
Journal:  Front Psychiatry       Date:  2021-03-31       Impact factor: 4.157

Review 10.  A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans.

Authors:  Elisabeth Prevete; Kim Paula Colette Kuypers; Eef Lien Theunissen; Ornella Corazza; Giuseppe Bersani; Johannes Gerardus Ramaekers
Journal:  Hum Psychopharmacol       Date:  2021-07-26       Impact factor: 2.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.